Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007

TheFly reported connected January 20 that Clear Street downgraded JANX to Hold from Buy and lowered the terms people to $12 from $32. The steadfast noted that the deficiency of wide durability signals from JANX007 and the lack of caller information from JANX008 present worldly level risk. The steadfast says that JANX besides faces rising competitory unit and an undefined way for JANX007, which increases execution risk.

Recently, connected January 22, Janux Therapeutics, Inc. (NASDAQ:JANX) and Bristol Myers (NYSE: BMY) announced an exclusive worldwide licence and collaboration statement to make a caller tumor-activated therapy that targets a coagulated tumor antigen that has been validated. The statement states that erstwhile JANX completes preclinical improvement done IND filing, Bristol Myers volition clasp the IND and supervise planetary improvement and commercialization.

In summation to tiered royalties connected planetary sales, JANX is qualified for up to $50 cardinal successful upfront and near-term milestones, arsenic good arsenic aboriginal development, regulatory, and commercialized milestones totaling implicit $800 million. JANX volition enactment the archetypal Phase 1 objective investigation.

Janux Therapeutics, Inc. (NASDAQ:JANX) is simply a clinical‑stage biotechnology institution that develops caller immunotherapies that activate innate and adaptive immune responses to dainty cancer. Its pipeline focuses connected engineered cytokine and receptor‑targeted therapies designed to heighten antitumor enactment with improved safety.

While we admit the imaginable of JANX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.